According to its SEC 13F filed on Feb 17, 2026, Iron Triangle Partners reported 27 long positions worth $875M as of Dec 31, 2025. CRL is 8.7% of the portfolio and the top 10 holdings are 53%. Against Q3 2025 it opened 16 new positions, added to 8, trimmed 3 and exited 14. 5 holdings have a dated FDA decision or data readout in the next 90 days, and 4 more expect one in a stated window such as "H2 2026".
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
BKD | BROOKDALE SR LIVING INC | 3.49 M | 37.68 M | 4.3 | Added +23% | — | None in 90 days | ||
NVST | ENVISTA HOLDINGS CORPORATION | 1.19 M | 25.76 M | 2.9 | New | Commercial | None in 90 days | ||
BHVN | BIOHAVEN LTD | 958.34 K | 10.82 M | 1.2 | New | Clinical | Oct 23, 2026 Phase 1 data readout | ||
BTSG | BRIGHTSPRING HEALTH SVCS INC | 897.43 K | 33.61 M | 3.8 | Trimmed -28% | — | None in 90 days | ||
JAZZ | JAZZ PHARMACEUTICALS PLC | 292.17 K | 49.67 M | 5.7 | Added +95% | Commercial | Expected Q4 2026 Phase 3 data presentation | ||
DNTH | DIANTHUS THERAPEUTICS INC | 230.73 K | 9.51 M | 1.1 | New | Clinical | Expected 2H 2026 Phase 2 topline data readout |
Size = share of the portfolio. Option positions show CALL or PUT.
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
27 stocks worth $875M at Dec 31, 2025, as reported in its 13F, led by CRL (8.7% of the portfolio). The full list is in the Holdings table above.
Against Q3 2025: 16 new positions, 8 increases, 3 reductions and 14 full exits, from its 13F filings.
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by IRON TRIANGLE PARTNERS LP, accession 0001172661-26-000928, filed Feb 17, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.